Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | IDE | P14735 | 1/20 | 0.59 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426669 | 1.00 | KMT2A (0.72) | KMT2AALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL4363340 | 0.88 | ALDH1A1 (0.67) | KMT2AALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL4363345 | 0.88 | ALDH1A1 (0.67) | KMT2AALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL13464888 | 0.85 | KMT2A (0.76) | KMT2AALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL13616323 | 0.85 | RAB9A (0.76) | KMT2AALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL15604194 | 0.84 | KMT2A (0.74) | KMT2AALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL4354203 | 0.83 | ALDH1A1 (1.00) | KMT2AALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL4354199 | 0.83 | ALDH1A1 (1.00) | KMT2AALDH1A1MAPTHTTSMN1; SMN2 | |
| Bromide SCHEMBL4346491 | 0.82 | ALDH1A1 (0.97) | KMT2AALDH1A1MAPTHTTSMN1; SMN2 | |
| Bromide SCHEMBL4346488 | 0.82 | ALDH1A1 (0.97) | KMT2AALDH1A1MAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250167-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | Chlorion Pharma, Inc. (CA) | 2010-11-17 | — | — | EP | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| WO-2009097695-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | CHLORION PHARMA, INC. (CA) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | OPRL1, OPRK1, AHR | KMT2A 1752/4885ALDH1A1 211/4885MAPT 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.